New Drug Delivery System Could Reduce the Dose Needed to Treat Pancreatic Cancer

A Massachusetts General Hospital research study suggests that a nanoparticle drug-delivery system that combines two complementary types of anticancer treatment could improve outcomes for patients with pancreatic cancer and other highly treatment-resistant tumors, while decreasing treatment toxicity. The new system, which combines a light-activated nanoparticle with a molecular therapy drug, reduced the dosage required to suppress tumor progression and metastatic outgrowth by 1,000 percent. Tayyaba Hasan, PhD, of the Wellman Center for Photomedicine is the corresponding author of the study.

 

Leave a Reply